Breast cancer is one of the most common cancers in China - and it is on the rise

George ClinicalAmong women in China, rates of breast cancer rose around 3.5% each year between 2000 and 2013. In comparison, breast cancer among American women decreased by about 0.4% a year over the same timeframe. China's rapid urbanisation and development of multiple 'megacities' - a city with 10 million or more inhabitants - reveals higher rates of breast cancer in urban areas, and in more densely-populated areas. In Chinese cities where the population is 1 million or more, the incidence of breast cancer is 60 per 100,000 women.

Dr. Lee Schwartzberg, Executive Director of the West Cancer Center, a leading oncology research and treatment practice, and oncology scientific lead at George Clinical says the increase in breast cancer among women in China is likely due to many factors.

"There are various risk factors associated with breast cancer. These include being less physically active, consuming alcohol or having an unhealthy diet. For women, reproductive factors, like having fewer children, might increase risk."

China's notorious one-child policy was in place from the late 1970s until 2015 (when it was replaced with a two-child policy) and reduced the country's birth rate. The average age of women at the birth of their first child has also risen, as has contraceptive use, and rates of breastfeeding - which has been linked to a reduced risk of breast cancer - have declined.

Twenty years ago, the state of public health in China was similar to most countries in the developing world. Now, thanks to urbanisation and the country's economic growth, China is facing health issues more commonly seen in wealthier countries like the UK or the US. Chronic and non-infectious diseases have been increasing in China, driven by higher incomes, an ageing population, and higher urban density. "These benefits of a growing economy may contribute to greater cancer risk for China's population," says Dr. Schwartzberg. Increased stress levels, associated with larger cities, may affect the immune system or hormones, and encourage the growth of cancer. Similarly, ageing is a critical factor in the incidence of breast cancer: women in China are living longer than ever. Screening for breast cancer in the country faces challenges, with low coverage and variations in different geographic regions.

The general risk factors associated with chronic disease and cancers also likely contribute to the rise in breast cancer rates in China. Rates of physical activity among women in China have decreased, rates of obesity have increased, and alcohol intake - which is associated with increased risk for several cancers including breast cancer - has risen in China.

China's increase in rates of chronic disease is a sign of its increased prosperity over the last twenty years. However, many of the risks associated with breast cancer among women can be reduced or avoided, by raising cancer awareness and improving knowledge on diet, exercise, and breast cancer screening.

For further information about George Clinical, please visit:
https://www.georgeclinical.com/therapeutic-expertise/oncology-cro

George Clinical is a leading independent Asia-Pacific based clinical research organisation (CRO) with global capabilities differentiated by scientific leadership, innovation, and extensive investigator networks. With staff operating in over 15 countries, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials. George Clinical combines scientific and clinical leadership with expert trial delivery capability to create a distinctive world-class service.

Most Popular Now

US FDA grants Lynparza Orphan Drug Designation for…

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by ...

FDA approves new drug to treat influenza

The U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older...

Eating leafy greens could help prevent macular deg…

A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-relat...

Alcon to develop SMART Suite digital health platfo…

Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is design...

Amgen launches AMGEVITATM (biosimilar adalimumab) …

Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimum...

Boehringer Ingelheim increases awareness of health…

Boehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 20...

Targeted drugs for advanced cancer move from speci…

Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutation...

Novartis 5-year data in psoriatic arthritis and an…

Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and ...

FDA approves asthma indication for Dupixent® (dupi…

The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and old...

Largest census of cancer genes to help understand …

Researchers at the Wellcome Sanger Institute have created the first comprehensive summary of all genes known to be involved in human cancer, the "Cancer Gene Census". Des...

Diets rich in fish oil could slow the spread and g…

Omega-3 fatty acids, such as those typically contained in fish oil, may suppress the growth and spread of breast cancer cells in mice. This is according to a new study in...

Novartis announces clinical collaboration with Pfi…

Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer comp...